1. Scrip
  2. >>Business

INTERVIEW: Juno CEO Hans Bishop On The CAR-T Learning Curve

 
• By Mandy Jackson

Juno Therapeutics President and CEO Hans Bishop spoke with Scrip about the company's CAR-T strategy, its short-lived clinical hold and Novartis's recent cell therapy business shift.

Bishop Hans, Juno
Juno Therapeutics Inc. President and CEO Hans Bishop • Source: Juno Therapeutics Inc.

Immuno-oncology drug developers are generating a flood of new information about how to safely boost the immune system's ability to fight cancer and Juno Therapeutics Inc. is standing in front of the firehose trying to make sense of the data.

Juno's President and CEO Hans Bishop said in an interview with Scrip that one of the company's goals is to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Amgen’s MariTide Data Not The Hit Investors Sought

 
• By Joseph Haas

MariTide demonstrated solid 52-week weight loss in a Phase II update, but high rates of vomiting. Amgen is adjusting dosing in Phase III to seek a better tolerability profile.

Positive Fabry Data Should Smooth Way For Sangamo’s Partnering Efforts

 
• By Alaric DeArment

The biotech announced results from the pivotal trial of isaralgagene civoparvovec and plans to file for approval in 2026 as it looks for a commercialization partner.

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By Kevin Grogan

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.

More from Scrip

Stock Watch: When The Biotech Bandwagon Music Stops

 
• By Andy Smith

The number of viable biotech companies exploiting a particular technology should be limited by intellectual property but the number of biotech IPOs exploiting that same technology always seems greater than those with freedom to operate.

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 
• By Andrew McConaghie

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.